https://www.insurerbrain.com/w/index.php?action=history&feed=atom&title=Definition%3AGeneric_drugDefinition:Generic drug - Revision history2026-06-13T16:01:06ZRevision history for this page on the wikiMediaWiki 1.43.8https://www.insurerbrain.com/w/index.php?title=Definition:Generic_drug&diff=11038&oldid=prevPlumBot: Bot: Creating new article from JSON2026-03-11T17:18:23Z<p>Bot: Creating new article from JSON</p>
<p><b>New page</b></p><div>💊 '''Generic drug''' is a pharmaceutical product that contains the same active ingredient, dosage form, strength, and route of administration as a branded original but is sold without the brand name — and in the context of [[Definition:Health insurance | health insurance]] and [[Definition:Pharmacy benefit management | pharmacy benefit management]], generics are one of the most consequential levers for controlling [[Definition:Claims cost | claims costs]] and shaping [[Definition:Formulary | formulary]] design. [[Definition:Insurance carrier | Carriers]] offering medical and [[Definition:Prescription drug coverage | prescription drug coverage]] rely on the availability of generics to keep [[Definition:Loss ratio (L/R) | loss ratios]] sustainable, especially in group and individual health plans where pharmaceutical spending can dominate total [[Definition:Paid loss | paid losses]].<br />
<br />
🔄 Once a brand-name drug's patent protection and regulatory exclusivity period expire, manufacturers may produce and market generic equivalents after obtaining approval from the relevant regulatory authority. [[Definition:Pharmacy benefit manager (PBM) | Pharmacy benefit managers]] and health insurers then incorporate these generics into tiered formularies, typically placing them on the lowest-cost tier to incentivize [[Definition:Policyholder | policyholder]] use through reduced [[Definition:Copayment | copayments]] or [[Definition:Coinsurance | coinsurance]]. In [[Definition:Workers' compensation insurance | workers' compensation]] and [[Definition:Auto insurance | auto insurance]] medical payments coverage, [[Definition:Claims adjuster | adjusters]] and [[Definition:Utilization review | utilization review]] teams similarly steer treatment toward generics when clinically appropriate, producing measurable savings that flow directly to the insurer's [[Definition:Underwriting profit | underwriting result]].<br />
<br />
📉 From a broader industry perspective, the pace of generic entry into the market has a material effect on medical [[Definition:Loss trend | loss trends]] and [[Definition:Rate filing | rate filings]]. When a blockbuster drug goes off-patent, the resulting cost reduction can noticeably bend a carrier's claims curve downward, influencing [[Definition:Actuarial analysis | actuarial assumptions]] and [[Definition:Premium | premium]] adequacy assessments. Conversely, delays in generic availability — whether from patent litigation or supply-chain disruptions — can spike costs unexpectedly. For [[Definition:Underwriter | underwriters]] and product designers, tracking the generic pipeline is therefore as important as monitoring hospital cost inflation when projecting future health plan performance.<br />
<br />
'''Related concepts:'''<br />
{{Div col|colwidth=20em}}<br />
* [[Definition:Pharmacy benefit manager (PBM)]]<br />
* [[Definition:Formulary]]<br />
* [[Definition:Health insurance]]<br />
* [[Definition:Medical loss ratio (MLR)]]<br />
* [[Definition:Utilization review]]<br />
* [[Definition:Workers' compensation insurance]]<br />
{{Div col end}}</div>PlumBot